Compound research
NAD+ (Nicotinamide Adenine Dinucleotide) Precursors: Research Overview & Current Status
NAD+ (Nicotinamide Adenine Dinucleotide) Precursors is a Metabolic coenzyme / coenzyme precursor (not a peptide — small-molecule NAD+ biosynthesis intermediates). Current research status: in clinical trials. NMN and NR are studied as dietary-supplement-category compounds with an active human clinical trial base, but neither has FDA approval as a drug for any indication; the FDA has taken the position that NMN does not qualify as a lawful dietary supplement ingredient in some contexts due to prior investigational new drug (IND) status, a matter that has seen ongoing regulatory back-and-forth.
Overview
NAD+ is an essential coenzyme involved in cellular energy metabolism and redox reactions, with levels known to decline with age. Research in this space centers on precursor molecules — primarily nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — that are metabolized into NAD+, rather than on NAD+ itself, which is not efficiently absorbed intact.
Metabolic coenzyme / coenzyme precursor (not a peptide — small-molecule NAD+ biosynthesis intermediates)
Research timeline
2010s
Animal studies established that NAD+ levels decline with aging and that boosting NAD+ via NMN or NR supplementation can increase health parameters and lifespan in aging animal models.
Source →2023
Preclinical stable-isotope tracing study reported that exogenous NMN is primarily converted to nicotinamide and then to NR before being used for NAD+ synthesis, suggesting NR may be a more direct/efficient precursor.
Source →2024
FASEB Scientific Research Conference on NAD Metabolism and Signaling highlighted growing 'bench to clinic' research interest and individual variability in response to NAD+ precursors.
Source →2025
Systematic review and meta-analysis on skeletal muscle mass/function found NMN/NR research promising for age-related sarcopenia but evidence in older adults remains inconclusive.
Source →2025
Geromedicine-focused systematic review of RCTs (2020-2025) compiled completed trials of NAD+ precursors in Alzheimer's disease, mild cognitive impairment, Parkinson's disease, and peripheral artery disease.
Source →2025-2026
Head-to-head human trial published in Nature Metabolism directly compared NMN, NR, and nicotinamide (Nam), finding NMN and NR each approximately doubled circulating NAD+ over 14 days while Nam did not sustain the increase; gut bacteria conversion to nicotinic acid (NA) was implicated as a mechanism.
Source →
Active & recent research
Head-to-head human comparison of NMN, NR, and nicotinamide
Direct comparison of circulating NAD+ increases among three precursor forms and the role of gut microbiome conversion
NMN/NR effects on skeletal muscle mass and function
Evaluating evidence for NAD+ precursor supplementation on age-related sarcopenia; found inconclusive in older adults
NAD+ precursors in neurodegenerative and vascular disease
Compiling completed clinical trials of NAD+ precursors in Alzheimer's disease, MCI, Parkinson's disease, and peripheral artery disease
Key findings
- A recent head-to-head human trial (Nature Metabolism) reported that both NMN and NR approximately doubled circulating NAD+ levels after 14 days of supplementation, while nicotinamide alone produced only a transient increase.
- That trial identified gut bacterial conversion of NMN and NR into nicotinic acid (NA) as a proposed mechanism for raising circulating NAD+, adding nuance to earlier assumptions about direct cellular uptake.
- A 2025 systematic review and meta-analysis on skeletal muscle outcomes concluded that while NMN/NR are of interest for age-related sarcopenia, current evidence in older adults remains inconclusive and requires larger, longer trials.
- A 2023 preclinical stable-isotope tracing study suggested NMN must first be converted to nicotinamide and then NR before contributing meaningfully to NAD+ synthesis, an important caveat for interpreting comparative efficacy claims between the two precursor forms.
Safety & regulatory notes
NMN and NR are marketed as dietary supplements in some jurisdictions rather than as approved drugs; neither has FDA approval for treating any disease. The FDA has at various points taken the position that NMN's earlier investigational new drug (IND) status may preclude its lawful marketing as a dietary supplement ingredient, an unresolved and evolving regulatory question distinct from safety per se. Clinical trials to date have generally reported these precursors as well-tolerated over the trial durations studied, but long-term safety data in diverse populations remain limited.
We may earn a commission when readers buy through links on this page, at no extra cost to you. Commissions never affect a vendor's score — every vendor is graded on the same public rubric built from published lab documentation, live catalog pricing, and community sentiment. How we score →
Where it's sold for research
We haven't built a dedicated vendor-availability page for NAD+ (Nicotinamide Adenine Dinucleotide) Precursors yet. See our full research-peptide vendor rankings →
NAD+ (Nicotinamide Adenine Dinucleotide) Precursors FAQ
Are NMN and NR the same as NAD+?+
No. NAD+ itself is not efficiently absorbed when taken orally; NMN and NR are precursor molecules that the body converts into NAD+, and most human research focuses on these precursors rather than NAD+ directly.
Is NMN FDA-approved?+
No. NMN has no FDA approval as a drug, and its regulatory status as a dietary supplement ingredient has been contested by the FDA due to its earlier investigational new drug status — this is a distinct, unresolved regulatory question, not a safety approval.
What does recent human research show about NMN vs. NR?+
A recent head-to-head human trial found both NMN and NR raised circulating NAD+ levels by a similar magnitude (roughly doubling it) over 14 days, while plain nicotinamide did not sustain the increase, with gut bacteria implicated in the conversion process.
Has NAD+ precursor supplementation been shown to reverse aging or extend human lifespan?+
No robust human evidence supports lifespan extension claims; the human research base focuses on measurable biomarkers like circulating NAD+ levels and specific disease-related outcomes, and reviews describe evidence in areas like sarcopenia as still inconclusive.
Sources for this page (5)
- 1 https://iadns.onlinelibrary.wiley.com/doi/10.1002/fft2.511
- 2 https://www.nmn.com/news/scientists-unveil-results-from-human-trial-directly-comparing-three-nad-precursors
- 3 https://pmc.ncbi.nlm.nih.gov/articles/PMC12022230/
- 4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579426/
- 5 https://sciexplor.com/articles/Geromedicine.2025.0008
Related: all compound research overviews · research radar · full vendor rankings · methodology